vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and Telesat Corp (TSAT). Click either name above to swap in a different company.
Telesat Corp is the larger business by last-quarter revenue ($73.8M vs $66.0M, roughly 1.1× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -119.8%, a 159.2% gap on every dollar of revenue.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
Telesat, formerly Telesat Canada, is a Canadian satellite communications company founded on May 2, 1969. The company is headquartered in Ottawa.
SLNO vs TSAT — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $73.8M |
| Net Profit | $26.0M | $-88.4M |
| Gross Margin | 98.3% | 95.3% |
| Operating Margin | 33.5% | 5.9% |
| Net Margin | 39.4% | -119.8% |
| Revenue YoY | — | — |
| Net Profit YoY | 134.0% | — |
| EPS (diluted) | $0.47 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $66.0M | $73.8M | ||
| Q2 25 | $32.7M | $77.5M | ||
| Q1 25 | — | $152.2M | ||
| Q2 24 | — | $363.2M | ||
| Q3 23 | — | $552.5M | ||
| Q2 23 | — | $372.4M | ||
| Q1 23 | — | $185.8M | ||
| Q3 22 | — | $570.7M |
| Q3 25 | $26.0M | $-88.4M | ||
| Q2 25 | $-4.7M | $55.1M | ||
| Q1 25 | — | $-52.3M | ||
| Q2 24 | — | $547.4M | ||
| Q3 23 | — | $-172.5M | ||
| Q2 23 | — | $56.3M | ||
| Q1 23 | — | $60.6M | ||
| Q3 22 | — | $42.1M |
| Q3 25 | 98.3% | 95.3% | ||
| Q2 25 | 97.9% | 95.9% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 33.5% | 5.9% | ||
| Q2 25 | -20.0% | 16.8% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 39.4% | -119.8% | ||
| Q2 25 | -14.4% | 71.2% | ||
| Q1 25 | — | -34.4% | ||
| Q2 24 | — | 150.7% | ||
| Q3 23 | — | -31.2% | ||
| Q2 23 | — | 15.1% | ||
| Q1 23 | — | 32.6% | ||
| Q3 22 | — | 7.4% |
| Q3 25 | $0.47 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $352.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $1.6B |
| Total Assets | $599.9M | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $498.9M | $352.3M | ||
| Q2 25 | $286.8M | $399.6M | ||
| Q1 25 | — | $552.1M | ||
| Q2 24 | — | $1.7B | ||
| Q3 23 | — | $1.7B | ||
| Q2 23 | — | $1.7B | ||
| Q1 23 | — | $1.7B | ||
| Q3 22 | — | $1.4B |
| Q3 25 | $494.8M | $1.6B | ||
| Q2 25 | $240.1M | $1.7B | ||
| Q1 25 | — | $2.5B | ||
| Q2 24 | — | $2.4B | ||
| Q3 23 | — | $1.8B | ||
| Q2 23 | — | $1.8B | ||
| Q1 23 | — | $1.8B | ||
| Q3 22 | — | $1.7B |
| Q3 25 | $599.9M | $5.1B | ||
| Q2 25 | $332.3M | $4.9B | ||
| Q1 25 | — | $6.9B | ||
| Q2 24 | — | $6.3B | ||
| Q3 23 | — | $6.5B | ||
| Q2 23 | — | $6.5B | ||
| Q1 23 | — | $6.5B | ||
| Q3 22 | — | $6.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | — |
| Free Cash FlowOCF − Capex | $43.5M | — |
| FCF MarginFCF / Revenue | 65.8% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-12.6M | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | $43.5M | — | ||
| Q2 25 | $-12.6M | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 65.8% | — | ||
| Q2 25 | -38.6% | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
